Changes in Hong Kong stocks | Jiangxi Biotech (06915) rose more than 6% and its Chifeng Boen veterinary tetanus antitoxin production line was officially put into operation

The Zhitong Finance App learned that Jiangxi Biotech (06915) rose by more than 6%. As of press release, it had risen 6.25% to HK$13.61, with a turnover of HK$347.22,300.

According to the news, on July 27, Jiangxi Biotech announced that the veterinary tetanus antitoxin (veterinary TAT) production line of Chifeng Boen Pharmaceutical Co., Ltd. (Chifeng Boen), a wholly-owned subsidiary of the company, was officially put into operation on July 20, 2026 in Chifeng City, Inner Mongolia Autonomous Region.

The board of directors believes that this commissioning marks key progress in the Group's “human drug+veterinary medicine” two-wheel drive strategy, expanding the Group's antiserum product layout from the human field to the animal health field, providing production capacity guarantees for large-scale production and commercialization of veterinary antiserum products, effectively enriching the Group's multi-category portfolio of antiserum products, and strengthening business growth momentum.